The Career Development Program received an evaluation of """"""""outstanding to excellent"""""""" at the last review. It was praised for the productivity of the six individuals supported thus far and it was noted that """"""""past success is quite indicative of their ability to identify candidates who are likely to have a successful research career in translational research."""""""" It was criticized because of concerns about supporting under-represented minority candidates and the feeling that """"""""decision factors for termination of support for career development recipient[s]are not adequately detailed."""""""" In this revised application the same general plan of solicitation and evaluation of applications, mentoring, and monitoring that has served us so well is maintained. The focus on support of faculty members rather senior trainees has been preserved because this has been such a successful strategy for our SPORE and because other sources for postdoctoral funding are available. Updated information about the progress of the six Career Development Award (CDA) recipients is provided. It is noteworthy that all six continue to serve as active faculty members in the Breast Cancer Program of the Sidney Kimmel Comprehensive Cancer Center (SKCCC) at Johns Hopkins. Five of the six have received independent peer-reviewed funding including three individuals who now hold R01s as principal investigator, one who serves as project leader on a Department of Defense Center of Excellence in Breast Cancer and one researcher who has been selected about selection as a Department of Defense Era of Hope Scholar. Two CDA recipients also received K-type career development funding from the National Cancer Institute. All have published in their fields of interest. Two CDA recipients are now serving as Project Co-leaders in this SPORE application. In the next funding cycle, the policy of awarding two Career Development Awards each year will be continued. Our tradition of providing $50,000/year to support the salary and fringe benefits of the recipient to ensure protected time for research will be maintained. In addition, in line with the revised 2005 interim SPORE guidelines, the SKCCC will provide $50,000 in supplementary funds each year to the Breast Cancer SPORE to support $25,000 in research costs for each recipient. No recipient will be funded for more than two years as stipulated by the 2005 interim SPORE guidelines. An application for one possible candidate for support in the next year of funding, Scott Kominsky, Ph.D., Assistant Professor of Orthopedic Surgery, is provided. Members of the Breast Cancer SPORE leadership as well as the Breast Cancer Program of the SKCCC have agreed that the second CDA position would be used to support the recruitment of a new translational breast cancer faculty member, a strategic goal articulated by the SKCCC Breast Cancer Program at the time of its competitive review in October, 2005.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
5P50CA088843-07
Application #
7726893
Study Section
Special Emphasis Panel (ZCA1)
Project Start
Project End
Budget Start
2007-09-30
Budget End
2008-09-29
Support Year
7
Fiscal Year
2007
Total Cost
$100,000
Indirect Cost
Name
Johns Hopkins University
Department
Type
DUNS #
001910777
City
Baltimore
State
MD
Country
United States
Zip Code
21218
Lo, Pang-Kuo (2018) FOXF2 differentially regulates expression of metabolic genes in non-cancerous and cancerous breast epithelial cells. Trends Diabetes Metab 1:
Cravero, Karen; Medford, Arielle; Pallavajjala, Aparna et al. (2018) Biotinylated amplicon sequencing: A method for preserving DNA samples of limited quantity. Pract Lab Med 12:e00108
Connolly, Roisin M; Fackler, Mary Jo; Zhang, Zhe et al. (2018) Tumor and serum DNA methylation in women receiving preoperative chemotherapy with or without vorinostat in TBCRC008. Breast Cancer Res Treat 167:107-116
Connolly, Roisin M; Li, Huili; Jankowitz, Rachel C et al. (2017) Combination Epigenetic Therapy in Advanced Breast Cancer with 5-Azacitidine and Entinostat: A Phase II National Cancer Institute/Stand Up to Cancer Study. Clin Cancer Res 23:2691-2701
Lo, Pang-Kuo (2017) The controversial role of forkhead box F2 (FOXF2) transcription factor in breast cancer. PRAS Open 1:
Haffner, Michael C; Esopi, David M; Chaux, Alcides et al. (2017) AIM1 is an actin-binding protein that suppresses cell migration and micrometastatic dissemination. Nat Commun 8:142
Sunay, Melek M E; Foote, Jeremy B; Leatherman, James M et al. (2017) Sorafenib combined with HER-2 targeted vaccination can promote effective T cell immunity in vivo. Int Immunopharmacol 46:112-123
Parsons, Heather A; Beaver, Julia A; Cimino-Mathews, Ashley et al. (2017) Individualized Molecular Analyses Guide Efforts (IMAGE): A Prospective Study of Molecular Profiling of Tissue and Blood in Metastatic Triple-Negative Breast Cancer. Clin Cancer Res 23:379-386
Cidado, Justin; Wong, Hong Yuen; Rosen, D Marc et al. (2016) Ki-67 is required for maintenance of cancer stem cells but not cell proliferation. Oncotarget 7:6281-93
Lo, Pang-Kuo; Lee, Ji Shin; Liang, Xiaohui et al. (2016) The dual role of FOXF2 in regulation of DNA replication and the epithelial-mesenchymal transition in breast cancer progression. Cell Signal 28:1502-19

Showing the most recent 10 out of 282 publications